{"commentary":{"count":49,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":25,"youtube":12,"podcast":11,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05536141\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"ARC-20","nct_id":"NCT05536141","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=arc-20-nct05536141. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"ARC-20","arms":[{"description":"Participants will receive casdatifan orally once daily","label":"Dose Escalation Cohort 1","type":"EXPERIMENTAL"},{"description":"Participants will receive casdatifan orally once daily","label":"Dose Escalation Cohort 2","type":"EXPERIMENTAL"},{"description":"Participants will receive casdatifan orally twice daily","label":"Dose Escalation Cohort 3","type":"EXPERIMENTAL"},{"description":"Participants will receive casdatifan orally once daily","label":"Dose Escalation Cohort 4","type":"EXPERIMENTAL"},{"description":"Participants will receive casdatifan orally once daily","label":"Dose Escalation Cohort 5","type":"EXPERIMENTAL"},{"description":"Participants will receive casdatifan orally","label":"Dose Expansion Cohort 1","type":"EXPERIMENTAL"},{"description":"Participants will receive casdatifan orally","label":"Dose Expansion Cohort 2","type":"EXPERIMENTAL"},{"description":"Participants will receive casdatifan orally","label":"Dose Expansion Cohort 3","type":"EXPERIMENTAL"},{"description":"Participants will receive casdatifan orally with with cabozantinib orally","label":"Dose Expansion Cohort 4","type":"EXPERIMENTAL"},{"description":"Participants will receive casdatifan orally","label":"Dose Expansion Cohort 5","type":"EXPERIMENTAL"},{"description":"Participants will receive casdatifan orally","label":"Dose Expansion Cohort 6","type":"EXPERIMENTAL"},{"description":"Participants will receive casdatifan orally with zimberelimab infusion","label":"Dose Expansion Cohort 7","type":"EXPERIMENTAL"},{"description":"Participants will receive casdatifan orally","label":"Dose Expansion Cohort 8","type":"EXPERIMENTAL"},{"description":"Participants will receive casdatifan orally with zimberelimab infusion and ipilimumab infusion","label":"Dose Expansion Cohort 9","type":"EXPERIMENTAL"},{"description":"Participants will receive casdatifan orally with zimberelimab infusion and ipilimumab infusion","label":"Dose Expansion Cohort 10","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2029-03","type":"ESTIMATED"},"conditions":["Clear Cell Renal Cell Carcinoma","Solid Tumors"],"enrollment":{"count":362,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"casdatifan","type":"DRUG"},{"name":"Cabozantinib","type":"DRUG"},{"name":"Zimberelimab","type":"DRUG"},{"name":"Ipilimumab","type":"DRUG"}],"last_update":"2026-10-05","lead_sponsor":"Arcus Biosciences, Inc.","official_title":"A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2029-03","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number of participants with dose limiting toxicities (DLTs)","timeFrame":"Up to 4 months"},{"measure":"Number of participants with adverse events (AEs)","timeFrame":"Up to 4 months"}],"references":[],"start_date":{"date":"2022-10-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors","url":"https://clinicaltrials.gov/study/NCT05536141"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/arc-20-nct05536141"}